Loading...
Loading...
LYRA| Name | Value |
|---|---|
| Revenues | 0.5M |
| Cost of Revenue | 10.8M |
| Gross Profit | -10.3M |
| Operating Expense | 15.4M |
| Operating I/L | -16.5M |
| Other Income/Expense | 0.9M |
| Interest Income | 0.9M |
| Pretax | -15.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -15.6M |
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company specializing in integrated drug and delivery solutions for ear, nose, and throat diseases. Its XTreo technology platform enables targeted delivery of medicines to affected tissue with a single administration. The company's product candidates, including LYR-210 and LYR-220, focus on the treatment of chronic rhinosinusitis (CRS) and nasal polyps. By developing novel implantable drug matrices, Lyra Therapeutics aims to provide sustained relief to patients with these conditions, potentially generating revenue through the commercialization of these innovative localized treatment solutions.
